aminoflavone and oncrasin-1

aminoflavone has been researched along with oncrasin-1* in 1 studies

Other Studies

1 other study(ies) available for aminoflavone and oncrasin-1

Article	Year
Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. Cancer research, 2020, 04-01, Volume: 80, Issue:7 Identification of the molecular mechanism of action (MoA) of bioactive compounds is a crucial step for drug development but remains a challenging task despite recent advances in technology. In this study, we applied multidimensional proteomics, sensitivity correlation analysis, and transcriptomics to identify a common MoA for the anticancer compounds RITA, aminoflavone (AF), and oncrasin-1 (Onc-1). Global thermal proteome profiling revealed that the three compounds target mRNA processing and transcription, thereby attacking a cancer vulnerability, transcriptional addiction. This led to the preferential loss of expression of oncogenes involved in PDGF, EGFR, VEGF, insulin/IGF/MAPKK, FGF, Hedgehog, TGFβ, and PI3K signaling pathways. Increased reactive oxygen species level in cancer cells was a prerequisite for targeting the mRNA transcription machinery, thus conferring cancer selectivity to these compounds. Furthermore, DNA repair factors involved in homologous recombination were among the most prominently repressed proteins. In cancer patient samples, RITA, AF, and Onc-1 sensitized to poly(ADP-ribose) polymerase inhibitors both Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Female; Flavonoids; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Oncogenes; Oxidative Stress; Poly(ADP-ribose) Polymerase Inhibitors; Proteome; Proteomics; Recombinational DNA Repair; Signal Transduction; Synthetic Lethal Mutations; Transcription, Genetic	2020

Article

Year

Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds.

Cancer research, 2020, 04-01, Volume: 80, Issue:7

Identification of the molecular mechanism of action (MoA) of bioactive compounds is a crucial step for drug development but remains a challenging task despite recent advances in technology. In this study, we applied multidimensional proteomics, sensitivity correlation analysis, and transcriptomics to identify a common MoA for the anticancer compounds RITA, aminoflavone (AF), and oncrasin-1 (Onc-1). Global thermal proteome profiling revealed that the three compounds target mRNA processing and transcription, thereby attacking a cancer vulnerability, transcriptional addiction. This led to the preferential loss of expression of oncogenes involved in PDGF, EGFR, VEGF, insulin/IGF/MAPKK, FGF, Hedgehog, TGFβ, and PI3K signaling pathways. Increased reactive oxygen species level in cancer cells was a prerequisite for targeting the mRNA transcription machinery, thus conferring cancer selectivity to these compounds. Furthermore, DNA repair factors involved in homologous recombination were among the most prominently repressed proteins. In cancer patient samples, RITA, AF, and Onc-1 sensitized to poly(ADP-ribose) polymerase inhibitors both

Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Female; Flavonoids; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Oncogenes; Oxidative Stress; Poly(ADP-ribose) Polymerase Inhibitors; Proteome; Proteomics; Recombinational DNA Repair; Signal Transduction; Synthetic Lethal Mutations; Transcription, Genetic

2020